Carnitine Treatment Improved Quality-of-Life Measure in a Sample of Midwestern Hemodialysis Patients

摘要: Background: Previously, we demonstrated that selected groups of hemodialysis patients might be more likely to have abnormalities carnitine metabolism. The purpose the present study was examine effects therapy in these on quality-of-life measures and erythropoietin dose. Methods: This a double-blind, randomized, controlled trial, which 50 were treated with either 2 g IV or placebo. treatment period for 24 weeks. Results: Thirty-four (15 group) completed study. mean age 69 ± 15 years, 35% women, 44% had diabetes. Mean initial plasma total, free, short-chain acyl long-chain concentrations (μmol/L; SEM) 35.9 1.8, 18.2 1.1, 11.6 0.6, 6.0 0.3, whereas acyl-to-free-carnitine ratio 1.02 0.05. With respect Medical Outcomes Short Form-36 (SF-36), improvements from baseline noted ...